Adagrasib 600 mg orally twice daily or adagrasib in combination with cetuximab (400 mg/m2 followed by 250 mg/m2 every week or 500 mg/m2 every 2 weeks) were regimens evaluated in cohorts with pretreated metastatic KRAS G12C-mutant colon cancer. This evidence concerns the gene KRAS and malignant colon neoplasm.